This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, B. T.
Right arrow Articles by Quataert, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, B. T.
Right arrow Articles by Quataert, S. A.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, February 2005, p. 287-295, Vol. 12, No. 2
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.2.287-295.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Approach to Validating an Opsonophagocytic Assay for Streptococcus pneumoniae

Branda T. Hu,* Xinhong Yu, Thomas R. Jones, Carol Kirch, Sarah Harris, Stephen W. Hildreth, Dace V. Madore, and Sally A. Quataert

Applied Immunology & Microbiology, Wyeth Vaccines Research, Pearl River, New York

Received 31 August 2004/ Returned for modification 28 September 2004/ Accepted 9 December 2004

Streptococcus pneumoniae (pneumococcus) polysaccharide serotype-specific antibodies that have opsonophagocytic activity are considered a primary mechanism of host defense against pneumococcal disease. In vitro opsonophagocytic assays (OPAs) with antibody and complement to mediate opsonophagocytic killing of bacteria have been designed and developed as an adjunct to the standardized serum immunoglobulin G antipneumococcal capsular polysaccharide enzyme immunoassay to assess the effectiveness of pneumococcal vaccines. OPA presents challenges for assay standardization and assay precision due to the multiple biologically active and labile components involved in the assay, including human polymorphonuclear leukocytes or cultured effector cells, bacteria, and complement. Control of these biologically labile components is critical for consistent assay performance. An approach to validating the performance of the assay in accordance with International Conference for Harmonization guidelines, including its specificity, intermediate precision, accuracy, linearity, and robustness, is presented. Furthermore, we established parameters for universal reagents and standardization of the use of these reagents to ensure the interlaboratory reproducibility and validation of new methodologies.

* Corresponding author. Mailing address: Wyeth Vaccines Research, 401 N. Middletown Rd., 180/152A, Pearl River, NY 10965. Phone: (845) 602-3389. Fax: (845) 602-1885. E-mail: hubt{at}wyeth.com.

Clinical and Diagnostic Laboratory Immunology, February 2005, p. 287-295, Vol. 12, No. 2
1071-412X/05/$08.00+0     doi:10.1128/CDLI.12.2.287-295.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»